Navigation Links
Kendle Announces Details Regarding Third Quarter 2010 Earnings Conference Call and Webcast
Date:10/18/2010

CINCINNATI, Oct. 18 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL) announced today it will release its third quarter 2010 financial results after the market closes on Monday, Nov. 8, 2010. The Company will host a telephone conference call and simultaneous webcast on Tuesday, Nov. 9 at 8:30 a.m. Eastern Time. A question and answer session will follow.

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 946-0709. Participants outside North America should dial (719) 457-2632. All participants should enter conference ID number 5419062. A replay will be available through 5 p.m. Eastern Time on Dec. 9, 2010, by dialing (888) 203-1112 in North America or 719-457-0820 outside of North America and entering conference ID number 5419062.

Webcast Instructions

To access the live webcast, visit http://ir.kendle.com/phoenix.zhtml?p=irol-eventDetails&c=88712&eventID=3431689. Instructions for accessing the webcast are provided at the site. The webcast will be archived at www.kendle.com (click on "For Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Dec. 9, 2010.  Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

About Kendle

Kendle International Inc. (Nasdaq:

SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
2. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
3. Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference
4. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
5. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
6. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
7. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
8. Kendle Launches New Global Biostatistics Infrastructure
9. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
10. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
11. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  Beamz Interactive, Inc. (OTCQB: BZIC), ... today announced that it has signed an agreement ... supplier of innovative prosthetic, orthotic and assistive technology ... the agreement, RSL Steeper will promote and supply ... for use within UK residential care facilities through ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... 04, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc.'s lead drug ... the treatment of hot flashes associated with ... in the company's,double-blind, placebo- controlled, randomized Phase ... moderate to severe hot flashes,per week were ...
... analyses of progression-free survival in,the SPARC Phase ... risk of disease progression for patients receiving,satraplatin. ... well as presence or absence of pain., ... and GPC Biotech AG today announced the ...
Cached Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
(Date:12/19/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- A new ... -- moderate to severe hot flashes and night sweats ... bones. Hot flashes are common during menopause, affecting ... menopause also affect women after menopause, since they then ... "Our findings suggest women who exhibit moderate or ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Traveling through the ... measles virus to three others within a four-hour time ... a new report shows. "The exposures in this ... rather than an international terminal, highlighting the fact that ... Jared Vega, an infectious disease specialist at the U.S. ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 2014 A group of 127 scientists sent ... in reaction to a recent statement by the center that ... and derogated the efficacy of all brain exercises. , Signatories ... parts of the center’s statement critical of brain exercise companies ... also overstated its case, in a document it had entitled ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... in CT scanner technology have made perfusion computed tomography ... suspected stroke. Now, researchers at Mayo Clinic are working ... other CT images. Mayo Clinic medical physicist Cynthia McCollough, ... related to CT dose reduction at the 52nd Annual ...
... and Massachusetts believe the Earth has been getting warmer ... percent and 84 percent, respectively), and large majorities favor ... new public opinion research by Professor Jon Krosnick, a ... at Stanford University. Following up on a ...
... A major breakthrough in how to target and destroy ... been made by researchers at Wake Forest University Baptist ... to target and destroy Glioblastoma multiforme (GBM) cells without ... possibilities in cancer research previously not known to be ...
... found a new mechanism that explains how certain immune ... or pathological antibodies such as those present in autoimmune ... published online in the September issue of Nature ... Professor of Medicine at Mount Sinai School of Medicine, ...
... By Ellin Holohan HealthDay Reporter , TUESDAY, ... rising, their quality of life is falling, according to new ... healthy days per year that Americans lose due to obesity ... about 7.5 in 1993 to 17 in 2008. Researchers ...
... HealthDay Reporter , MONDAY, Aug. 2 (HealthDay News) ... A new two-year study suggests that it may not ... about eating and exercise, people lost about the same amount ... or a traditional low-fat diet. "In general, dieters should ...
Cached Medicine News:Health News:Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts 2Health News:New state surveys affirm Americans' support for government action on climate change 2Health News:New state surveys affirm Americans' support for government action on climate change 3Health News:Scientists develop 'designer protein,' opening new door in cancer research 2Health News:Scientists develop 'designer protein,' opening new door in cancer research 3Health News:New drug target for immune diseases discovered 2Health News:Weight Gain Eroding Americans' Quality of Life 2Health News:Weight Gain Eroding Americans' Quality of Life 3Health News:Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss 2Health News:Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss 3
... primer combinations in the PCR amplification. It ... primers whose sequence is completely complementary to ... the polymerase into PCR products. In contrast, ... the Biotest SSP Kit Systems, reliable typing ...
... constructed with built-in bags as in a suspension ... placed without contacting the ethylene glycol and without ... device ensures easy handling and maximum surface freezing ... that the relatively hot air under the lid ...
It includes 99 single plasma units. Model 8001 (8003), includes 11 roll-out drawers containing removable wire baskets....
... PillCam SB Capsule Endoscope is a ... the gastrointestinal tract. Natural peristalsis moves ... painlessly throughout the gastrointestinal tract, transmitting ... The procedure is ambulatory, allowing patients ...
Medicine Products: